Intelacia Archives - Page 2 of 13

A drug does not become more valuable only by becoming more powerful. Sometimes, changing how it is delivered can...

•September 9, 2026•Surbhi Ashri

Micro-Robots Changing Brain Surgery – Real Breakthrough Is How They Move

A Paris-based startup is developing a 1.8 mm-long robot designed to travel inside the brain. Robeauté raised $28 million in...

Intelacia

•September 7, 2026•Surbhi Ashri

When the Implant Starts Watching You: The IP and Privacy Risks of Always-On Medical Sensors

Medical implants are moving beyond treatment. A new generation of flexible and implantable sensors is being designed...

Intelacia

•September 4, 2026•Surbhi Ashri

Per- and Polyfluoroalkyl Substance Replacement Chemistry: The Race for What Comes Next

The EU has introduced numerical PFAS limits for food-contact packaging. The U.S. has upheld Superfund liability for...

Intelacia

•September 2, 2026•Surbhi Ashri

Medical Device M&A: Two Edwards Deals and Two FTC Problems

For medical-device companies, antitrust risk used to be relatively easy to frame: look at market share, identify overlapping products, assess the deal value,...

Intelacia

•August 31, 2026•Surbhi Ashri

FDA Starts Shaping the Rulebook for Generative AI Medical Devices

The U.S. Food and Drug Administration (FDA) has opened a new regulatory discussion around one of the...

Intelacia

•August 26, 2026•Surbhi Ashri, Varun Raheja

When the AI Is Right but the User Is Wrong: FDA’s New Focus on Medical Device Usability

A medical device can produce the right answer and still be unsafe. That is becoming an increasingly...

Intelacia

•August 21, 2026•Surbhi Ashri

News Corp vs. Brave: The Copyright Battle Over AI Summaries

Artificial intelligence has transformed search engines into answer engines. Instead of directing users to websites, AI systems...

Intelacia

•August 19, 2026•Surbhi Ashri

PRIMA Retinal Implant: 2-mm Device Restores Vision

For patients who have lost central vision to advanced geographic atrophy, the problem is not simply that...

Intelacia

•August 17, 2026•Surbhi Ashri

Samsung Biologics PolyPeptide Deal: A $1.8B Bet on Peptides

The Samsung Biologics PolyPeptide deal, an all-cash transaction worth approximately CHF 1.46 billion (US$1.8 billion), represents more than a conventional pharmaceutical acquisition....

1 2 3 4 … 13

Category